A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).

被引：28
|
作者：
Wander, Seth Andrew
Zangardi, Mark
Niemierko, Andrzej
Kambadakone, Avinash
Kim, Leslie S. L.
Xi, Jing
Pandey, Apurva Kumari
Spring, Laura
Stein, Casey
Juric, Dejan
Kuter, Irene
Moy, Beverly
Mulvey, Therese Marie
Vidula, Neelima
Isakoff, Steven J.
Yuen, Megan
Brufsky, Adam
Ma, Cynthia X.
O'Shaughnessy, Joyce
Bardia, Aditya
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Texas Oncol, Dallas, TX USA
[4] St Lukes Hosp, Chesterfield, MO USA
[5] UPMC Mercy, Pittsburgh, PA USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA
[7] Southcoast Hosp Grp, Fall River, MA USA
[8] Massachusetts Gen Hosp, San Francisco, CA USA
[9] Univ Pittsburgh, Med Ctr, Div Hematol Oncol, Pittsburgh, PA USA
[10] Washington Univ, Sch Med St Louis, St Louis, MO 63110 USA
[11] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1057
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [2] Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2-metastatic breast cancer
    Dieras, V.
    Hamilton, E.
    Johnston, E. L.
    Forrester, T.
    Martin, M.
    [J]. CANCER RESEARCH, 2017, 77
  • [3] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [4] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2-metastatic breast cancer
    Li, Yi
    Li, Wei
    Gong, Chengcheng
    Zheng, Yabin
    Ouyang, Quchang
    Xie, Ning
    Qu, Qing
    Ge, Rui
    Wang, Biyun
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [6] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [7] Abemaciclib in HR+/Her2-metastatic breast cancer patients after previous progression on palbociclib or ribociclib: Clinical experience in a tertiary hospital in Madrid, Spain
    De Luna Aguilar, A.
    Moreno Anton, F.
    Benitez Fuentes, J. D.
    Ortega Anselmi, J.
    Olalla Inoa, J.
    Flores Navarro, P.
    Garcia Saenz, J. A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S219 - S220
  • [8] Real-world analysis of disease progression after CDK 4/6 inhibitor (CDKi) therapy in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC).
    West, Malinda
    Kaempf, Andy
    Goodyear, Shaun
    Kartika, Thomas
    Ribkoff, Jessica
    Mitri, Zahi Ibrahim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    [J]. CANCER RESEARCH, 2017, 77
  • [10] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    [J]. FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
12345